Menu
Back to Journals » Drug Design, Development and Therapy » Volume 7
Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
Received 14 May 2013
Accepted for publication 25 June 2013
Published 1 August 2013 Volume 2013:7 Pages 681—689
DOI https://doi.org/10.2147/DDDT.S41910
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Qian Ding, Jinbiao Zhan
Department of Biochemistry, Zhejiang University School of Medicine, Hangzhou, People's Republic of China
Abstract: Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer characterized by early metastasis and high mortality. In recent years, monotherapy and combination therapy of amrubicin with cisplatin or carboplatin has been actively studied and shown promise for the treatment of extensive disease SCLC (ED-SCLC). In this article, we summarize clinical trials of both monotherapy and combination therapy with amrubicin conducted in Japan, the USA, and the European Union. The results suggest that the clinical outcome of amrubicin therapy may be associated with genetic variations in patients. Further study of combination regimens in patients of different ethnicities is warranted.
Keywords: amrubicin, cisplatin, carboplatin, combination therapy, small-cell lung cancer, antibody-drug conjugates
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.